Routine use of zoledronic acid in early-stage breast cancer.
Journal Article (Journal Article;Review)
Zoledronic acid, a potent nitrogen-containing bisphosphonate, plays a key role in preventing complications of bone metastases in metastatic breast cancer, but its affect on early-stage breast cancer has been unclear. The preclinical data supporting the anticancer effects of zoledronic acid are compelling and several recent clinical trials have suggested that it reduces breast cancer recurrence in certain patient subgroups. Given these anticancer effects and reasonable safety profile, this therapeutic option could be discussed with patients. This article focuses on the results of supporting preclinical and clinical data evaluating the role of zoledronic acid in adjuvant breast cancer therapy.
Full Text
Duke Authors
Cited Authors
- Harnden, K; Blackwell, K
Published Date
- April 2015
Published In
Volume / Issue
- 13 / 4
Start / End Page
- 480 - 486
PubMed ID
- 25870382
Electronic International Standard Serial Number (EISSN)
- 1540-1413
Digital Object Identifier (DOI)
- 10.6004/jnccn.2015.0061
Language
- eng
Conference Location
- United States